BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Science Signaling

• Publication date

  2010-11-23

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1126/scisignal.2001148PMID 21098728PMCID PMC3372405
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of mutated, activated BRAF in metastatic melanoma.

  2010cited by this paper
• Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212.

  2010cited by this paper
• Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

  2010cited by this paper
• Identification of selective inhibitors of cancer stem cells by high-throughput screening.

  2009cited by this paper
• Oncogenic Activating Mutations Are Associated with Local Copy Gain

  2009cited by this paper
• MEK1 mutations confer resistance to MEK and B-RAF inhibition

  2009influential reference
• Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells

  2009cited by this paper
• Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology.

  2009cited by this paper
• Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.

  2008influential reference
• Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

  2008cited by this paper
• Colorectal cancer cells with the BRAFV600E mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM

  2008cited by this paper
• Discovery of a Cytokine and Its Receptor by Functional Screening of the Extracellular Proteome

  2008cited by this paper
• The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor

  2008cited by this paper
• Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation

  2008cited by this paper
• Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.

  2008cited by this paper
• Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth

  2007cited by this paper
• Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen.

  2006cited by this paper
• BRAF mutation predicts sensitivity to MEK inhibition

  2006cited by this paper
• Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

  2006cited by this paper
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

  2005cited by this paper
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

  2005cited by this paper
• Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.

  2004cited by this paper
• Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

  2004cited by this paper
• Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

  2003cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

  2001cited by this paper
• High-throughput screening

  1998cited by this paper
• Tumor and lymphoid cell lines from a patient with carcinoma of the colon for a cytotoxicity model.

  1978cited by this paper

• Third-line and beyond treatment in mCRC and sequencing

  2026cites this paper
• Defeating kinases that promote tumorigenesis through non-catalytic functions with PROTACs - PIM kinase as an example

  2025cites this paper
• Exploring the pathway: clinical utility and open challenges of targeting BRAF alterations in biliary tract cancers and gastrointestinal malignancies

  2025cites this paper
• Forecasting oncogene amplification and tumour suppressor deletion

  2025cites this paper
• Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review

  2025cites this paper
• The Slx4-Rad1-Rad10 nuclease differentially regulates deletions and duplications induced by a replication fork barrier

  2025cites this paper
• Acquired resistance to molecularly targeted therapies for cancer

  2025cites this paper
• Comparative molecular analysis of primary and recurrent pleomorphic xanthoastrocytoma with BRAF mutation treated with combination therapy with dabrafenib and trametinib: a case report and literature review

  2025cites this paper
• Same mutation, different fates: The Yin-Yang of BRAF-driven therapeutic responses in melanoma and colorectal cancer.

  2025cites this paper
• Transposon mediated functional genomic screening for BRAF inhibitor resistance reveals convergent Hippo and MAPK pathway activation events

  2025cites this paper
• Extracellular vesicle-mediated gene therapy targets BRAFV600E-mutant colorectal cancer by inhibiting the MEK1/2-ERK1/2 pathway

  2025cites this paper
• RAS pathway targeted therapy in patients with DICER1-associated sarcomas

  2025cites this paper
• Evolving roles of MET as a therapeutic target in NSCLC and beyond

  2025cites this paper
• Rational Design of a Hydrophilic Perovskite Ultraviolet Photocatalyst for Mediating a Sensitive and Controllable Nucleic Acid Assay.

  2025cites this paper
• Challenges in the treatment of BRAF K601E-mutated lung carcinoma: a case report of rapid response and resistance to dabrafenib and trametinib

  2024cites this paper
• RhoA activation promotes glucose uptake to elevate proliferation in MAPK inhibitor resistant melanoma cells

  2024cites this paper
• Unsupervised Analysis Reveals the Involvement of Key Immune Response Genes and the Matrisome in Resistance to BRAF and MEK Inhibitors in Melanoma

  2024cites this paper
• Molecular Susceptibility and Treatment Challenges in Melanoma

  2024cites this paper
• Drug-resistant BRAF V600E-mutant recurrent pleomorphic xanthoastrocytoma, CNS WHO Grade 3 successfully resolved with incidental discontinuation of combined BRAF and MEK inhibitor therapy

  2024influential citation
• Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer

  2024cites this paper
• Single-cell genomics analysis reveals complex genetic interactions in an in vivo model of acquired BRAF inhibitor resistance

  2024cites this paper
• Molecular Approach to Colorectal Carcinoma: Current Evidence and Clinical Application.

  2024cites this paper
• Melanoma redox biology and the emergence of drug resistance.

  2024cites this paper
• Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial

  2024cites this paper
• BRAF Expression and Copy Number Alterations Predict Unfavorable Tumor Features and Adverse Outcomes in Patients With Breast Cancer

  2024cites this paper
• MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer.

  2023cites this paper
• The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis.

  2023cites this paper
• Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study

  2023cites this paper
• Molecular mechanism and clinical outcome of non-small cell lung cancer patients with high BRAF expression

  2023cites this paper
• Integrative Structural Learning of Mixed Graphical Models via Pseudo-likelihood

  2023cites this paper
• Pharmacological inhibition of MEK1/2 signaling disrupts bile acid metabolism through loss of Shp and enhanced Cyp7a1 expression.

  2023cites this paper
• The BEETS (JACCRO CC-18) trial: an observational and translational study of BRAF-mutated metastatic colorectal cancer.

  2023cites this paper
• Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2

  2023cites this paper
• The Targeted Degradation of BRAF V600E Reveals the Mechanisms of Resistance to BRAF-Targeted Treatments in Colorectal Cancer Cells

  2023cites this paper
• Antitumor activity of the new tyrphostin briva against BRAFV600E-mutant colorectal carcinoma cells

  2023cites this paper
• Cross-Domain Feature Disentanglement for Interpretable Modeling of Tumor Microenvironment Impact on Drug Response

  2023cites this paper
• ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer

  2023cites this paper
• Proteasome inhibition potentiates Kv1.3 potassium channel expression as therapeutic target in drug-sensitive and -resistant human melanoma cells.

  2023cites this paper
• Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial

  2023cites this paper
• Molecularly targeted therapy in metastatic CRC

  2022cites this paper
• Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer

  2022cites this paper
• Conquering oncogenic KRAS and its bypass mechanisms

  2022cites this paper
• Structural optimization of 4-(imidazol-5-yl)pyridine derivatives affords broad-spectrum anticancer agents with selective B-RAFV600E/p38α kinase inhibitory activity: Synthesis, in vitro assays and in silico study.

  2022cites this paper
• UV-Induced Somatic Mutations Driving Clonal Evolution in Healthy Skin, Nevus, and Cutaneous Melanoma

  2022cites this paper
• Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

  2022cites this paper
• IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation

  2022cites this paper
• Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials.

  2022cites this paper
• Candidate therapeutic agents in a newly established triple wild‐type mucosal melanoma cell line

  2022cites this paper
• A pancancer analysis of the carcinogenic role of receptor-interacting serine/threonine protein kinase-2 (RIPK2) in human tumours

  2022cites this paper
• NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets

  2022cites this paper
• Targeting SHP2 sensitizes differentiated thyroid carcinoma to the MEK inhibitor.

  2022influential citation
• Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies

  2022cites this paper
• Intermittent treatment of BRAFV600E melanoma cells delays resistance by adaptive resensitization to drug rechallenge

  2022cites this paper
• Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers

  2022cites this paper
• Degraders: The Ultimate Weapon Against Amplified Driver Kinases in Cancer

  2022influential citation
• Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies

  2022cites this paper
• Efficacy of BRAF inhibitor and anti-EGFR antibody in colorectal neuroendocrine carcinoma

  2022cites this paper
• Thiazole and Related Heterocyclic Systems as Anticancer Agents: A Review on Synthetic Strategies, Mechanisms of Action and SAR Studies.

  2022cites this paper
• Escape from G1 arrest during acute MEK inhibition drives the acquisition of drug resistance

  2022cites this paper
• Treatment Options in BRAF-mutant Metastatic Colorectal Cancer

  2022influential citation
• Analysis of Copy Number Variations in Solid Tumors Using a Next Generation Sequencing Custom Panel

  2021cites this paper
• Autophagy Inhibition in BRAF-Driven Cancers

  2021cites this paper
• Molecular Approach to Colorectal Carcinoma: Current Evidence and Clinical Application.

  2021cites this paper
• Establishment and characterization of novel highly aggressive HER2-positive and triple-negative breast cancer cell lines

  2021cites this paper
• Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA

  2021cites this paper
• Systematic review of combinations of targeted or immunotherapy in advanced solid tumors

  2021cites this paper
• Modeling adaptive drug resistance of colorectal cancer and therapeutic interventions with tumor spheroids

  2021cites this paper
• Accurate quantification of T cells in copy number stable and unstable DNA samples using multiplex digital PCR.

  2021cites this paper
• Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma

  2021cites this paper
• Bilirubin Restrains the Anticancer Effect of Vemurafenib on BRAF-Mutant Melanoma Cells Through ERK-MNK1 Signaling

  2021cites this paper
• The Transcription Factor SLUG Uncouples Pancreatic Cancer Progression from the RAF–MEK1/2–ERK1/2 Pathway

  2021cites this paper
• Mechanisms of Resistance to Targeted Therapies in Skin Cancers

  2021cites this paper
• Precision oncology in metastatic colorectal cancer — from biology to medicine

  2021cites this paper
• Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy.

  2021cites this paper
• CYP27A1-dependent anti-melanoma activity of limonoid natural products targets mitochondrial metabolism.

  2021cites this paper
• Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer.

  2021cites this paper
• DNA replication during acute MEK inhibition drives acquisition of resistance through amplification of the BRAF oncogene

  2021influential citation
• Stimulation of adaptive gene amplification by origin firing under replication fork constraint

  2021cites this paper
• Resistance to Molecularly Targeted Therapies in Melanoma

  2021cites this paper
• RAF-MEK-ERK pathway in cancer evolution and treatment.

  2021cites this paper
• Effect of BRAF-mediated PI3K/Akt/mTOR pathway on biological characteristics and chemosensitivity of NSCLC A549/DDP cells

  2021cites this paper
• Allosteric Modulation of the Sigma-1 Receptor Elicits Antipsychotic-like Effects.

  2021cites this paper
• Selection of Oral Therapeutics in China for the Treatment of Colorectal Cancer

  2021cites this paper
• BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy

  2020cites this paper
• Identifying modules of cooperating cancer drivers

  2020cites this paper
• A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K-mutant Solid Tumors

  2020cites this paper
• Targeted Therapy in Melanoma and Mechanisms of Resistance

  2020cites this paper
• Role of the Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Cancer

  2020cites this paper
• Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update

  2020cites this paper
• New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients

  2020cites this paper
• N-acetylglycoside of oleanolic acid (aridanin) displays promising cytotoxicity towards human and animal cancer cells, inducing apoptotic, ferroptotic and necroptotic cell death.

  2020cites this paper
• Improvements in Clinical Outcomes for BRAFV600E-Mutant Metastatic Colorectal Cancer

  2020cites this paper
• The adaptive potential of circular DNA accumulation in ageing cells

  2020cites this paper
• Preliminary Study on the Identification of BRAFV600E Mutation in Colorectal Cancer by Near-Infrared Spectroscopy

  2020cites this paper
• Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma

  2020cites this paper
• Distinct genomic traits of acral and mucosal melanomas revealed by targeted mutational profiling

  2020cites this paper
• Precision Medicine in Metastatic Colorectal Cancer—Finding and Hitting the Right Targets

  2020cites this paper
• A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma

  2020influential citation
• Role and mechanism of autophagy‐regulating factors in tumorigenesis and drug resistance

  2020cites this paper
• Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review.

  2020cites this paper